Our partners' expertise and engagement are fundamental to drive long-term and measurable changes in cancer control for the benefit of the global cancer community.
Click on the logos here below to see more information about each partner.
The American Society for Clinical Pathology (ASCP) is the world’s largest professional membership organisation for pathologists and laboratory professionals. In addition to their educational and certification missions around the world, they maintain a very active global health delivery program focused on laboratory strengthening in all aspects. Through their 10 year + work with PEPFAR, they have improved HIV-related testing and access in ~20 countries, trained more than 3000 individuals, and continue to deliver innovated diagnostics their partners. The Cancer Diagnostics and Treatment in Africa Initiative, created and led by ASCP, aims for 100% access to diagnostics for patients with cancer through on-site assessment, implementation planning, and, ultimately, connectivity to experts around the world through telepathology. With more than 100,000 members, the society’s influence has guided the application and evolution of the pathology and laboratory medicine specialty since 1922. ASCP is leading the way in global health pathology.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
CUBEBIO is a biomedical company, headquartered in Seoul, South Korea, dedicated to researching and developing cancer diagnostic biomarkers and in vitro diagnostics. The company also possesses more than 30 patents in relation to cancer diagnosis. Since its establishment, CUBEBIO commits itself to the continuous research and development for global health improvements by detecting cancer early through self-diagnosis by means of urine as a specimen. CUBEBIO’s urine-based self-diagnostic technology enables anyone to check their cancer status fast, accurately, economically, and frequently, thereby making early screening possible and, in the case of cancer patients, allowing them to monitor their cancer for progression or recurrence.
CUBEBIO aims to enter world markets by fostering close working relations with cancer societies, foundations, and research centers in each and every country. By doing so, CUBEBIO works towards creating a new culture where complex cancer diagnostic procedure becomes simpler and more accessible by self-diagnosis, regardless of time and place, and thus emerges as a new global leader in the healthcare industry.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
The Astellas Group aims to become a R&D-driven global pharmaceutical company contributing to people’s health. Astellas’s business philosophy has three elements — raison d'être, mission and beliefs. This business philosophy expresses the company’s aim to contribute to the health of people around the world through the provision of highly effective and trustworthy pharmaceuticals, while continuously increasing the Company's enterprise value.
Founded in 1951 to support cancer research, the Swedish Cancer Society is an independent non-profit organization with the vision of finding cures for cancer. The overall aim of the Society is to achieve a higher survival rate and a reduction in the incidence of cancer. Their main task is to raise and distribute money for cancer research. As one of the largest financiers of cancer research in Sweden, the Swedish Cancer Society essentially acts as a national research council. Thanks to the organization’s extensive knowledge about cancer, the Swedish Cancer Society is also active in areas such as public opinion and spreading knowledge about cancer, as well as results of cancer research.
Established in 1984, the China Anti-Cancer Association (CACA) is a non-government and non-profit organisation with a mission to unite people involved in all branches of oncology with a shared interest in fighting cancer. CACA is dedicated to improving cancer control in China through increasing the survival rates, and decreasing the incidence and mortality rates of cancer. CACA plays an important role in promoting academic exchange, organising public education, establishing collaboration with international cancer societies, and providing data and advice to the Chinese government for making strategies and policies on cancer control. The branches consist of 45 professional societies, 47 full membership organisations, and 30 local anti-cancer associations with a total membership exceeding 47,000.
The German Cancer Society (DKG) is the largest scientific and specialist oncology company in Germany with headquarters in Berlin. They are engaged in cancer care on the basis of evidence-based medicine, interdisciplinary and consequent quality standards. In total, DKG has about 7600 members, organised in 24 working groups, 16 regional cancer societies and 34 sponsors from research-based pharmaceutical industries, scientific publishers and health insurances. Since cancers need to be cross-treated and researched, their members are not only medical doctors of all sections, but also basic researchers, medical technical assistants, nurses, psychologists and other professionals who work on cancer.
DKG specialises in certification of oncological care institutions, development of clinical practice guidelines, coordination of guidelines in the framework of the German Guideline Program of Oncology (GGPO), development and transfer of oncological knowledge, and improvement of information given to patients.
An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.
The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.
Friends of Cancer Patients UAE (FoCP UAE) charity is a non-profit organisation, founded in September 1999 under the directives and patronage of Her Highness Sheikha Jawaher Bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah, United Arab Emirates (UAE).
FoCP UAE provides a broad spectrum of support for its patients including financial support, which entails covering treatment expenses for chemotherapy, radiation and other needed medications, in addition to expenses for investigative and surgical procedures including bone marrow transplants and prosthetic limbs. FoCP UAE provides transportation and food allowance for underprivileged cancer patients and facilitates sending patients abroad for specialised treatment. FoCP UAE also provides moral support, offering cancer patients and their families psychological consultations and Hajj and Umrah services.
Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people.
The French National Cancer Institute (INCa) is the preeminent health and science agency in charge of cancer control in France, created under the Public Health Act of 9th August 2004. It reports to the ministries for Health and for Research.
The Institute is a public interest grouping (GIP) which brings together State representatives, charities, health insurance funds, research organisations and hospital federations. These stakeholders share a common goal of reducing the incidence of avoidable cancers and the number of cancer deaths, improving the quality of life of people with cancer during and after their illness, and reducing inequalities related to cancer.
The Institute provides an integrated approach encompassing all cancer-control dimensions (health, scientific, social and economic) and areas of intervention (prevention, screening, care and research) for the benefit of patients and their relatives.
To catalyse progress, the INCa acts as an interface with patients, their friends and families, the healthcare system users, general public, healthcare professionals, researchers, experts and decision-makers.
The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
The American Cancer Society is a global grassroots force of 2.5 million volunteers saving lives in every community. As the largest voluntary health organization, the Society’s efforts have contributed to a 25 percent decline in the cancer death rate in the U.S. since 1991, driven by less smoking, better treatments, and earlier detection. The American Cancer Society is finding cures as the United States largest private, not-for-profit investor in cancer research, ensuring people facing cancer have the help they need and continuing the fight for access to quality health care, lifesaving screenings and more. The Society’s global outreach efforts promote prevention and healthy living, reduce pain and suffering from cancer and help support cancer organizations in low and middle income countries, and provide a platform for advocacy and patient support in nearly 30 countries.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Biocon Limited is a globally recognized, innovation-led organization that is enabling access to high quality, advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.
The Canadian Partnership Against Cancer is an independent organisation funded by the federal government to accelerate action on cancer control for all Canadians. The Partnership works with cancer experts, charitable organisations, governments, cancer agencies, national health organisations, patients, survivors and others to achieve their shared goal of a future in which fewer Canadians get cancer, fewer die from it and those living with the disease have a better quality of life. The Partnership’s work spans the cancer control continuum, from prevention and screening to research and supportive care. Their collaborative approach is mindful of the patient voice, and strives to be culturally responsive to the needs of local communities.
Cancer Council is Australia’s leading cancer charity working across every aspect of every cancer. Every day, Cancer Council supports families affected by cancer when they need it most, works with the community to change laws and policies to reduce cancer risks and improve cancer care, empowers Australians to reduce their cancer risk, and funds more world-class cancer research than any other-non government organisation in Australia to reduce the impact of cancer. Thanks to the support of the Australian public, Cancer Council is getting closer to a cancer free future every minute, every hour, every day.
Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. They provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, their company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of their 15,000 employees worldwide, they create innovative new and generic medicines, and new methods of drug discovery and delivery. Daiichi Sankyo share a passion for innovation, as well as compassion for the patients around the world who are in need of their medicines.
Our Vision – Better Testing. Better Treatment.
Who we are – Diaceutics is the diagnostic development and commercialization service provider.
What we do – We have been leading this field for 13 years, entirely focused on the intersection between diagnostics and therapeutic decision making. We provide an end to end service that encompasses everything from understanding the diagnostic landscape to test implementation in treatment pathways. This is all enabled by a robust flow of data from our global laboratory network.
The Dutch Cancer Society is a nation-wide organization for cancer control in the Netherlands. The society was funded in 1949 by Queen Wilhelmina. Her granddaughter, Her Royal Highness Princess Beatrix, is the current patron. The Dutch Cancer Society’s ideal world is one in which nobody dies from cancer ever again. We want fewer people to get cancer, more people to cure, and patients to have a better quality of life, during and after the disease. That’s why we fund and facilitate scientific research, influence policy, and share our knowledge about cancer and its treatment. To make this possible, we raise funds and establish links with other parties involved in cancer control, both here in the Netherlands and elsewhere. The Dutch Cancer Society is entirely dependent on community involvement and donations. Over 100.000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advice in several councils and committees. We can rely on nearly 1.500 local committees that organize fundraising activities e.g. our annual door-to-door campaign to raise funds for the fight against cancer. The Dutch Cancer Society is supported by over 1 million donors. The Dutch Cancer Society’s office is located in Amsterdam; our professional staff amounts to 198 staff members.
Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. Its products and solutions include radiotherapy, stereotactic radiosurgery, oncology informatics, brachytheraphy, neurosurgery, and particle therapy.
The mission of Instituto Nacional de Cancerología is to develop health care, teaching and research excellence in oncology in Mexico. It aims to achieve this by being leaders in the generation of strategies for controlling cancer and reducing its impact as a public health problem in Mexico.
The McKinsey Cancer Center (McKCC) combines the extensive cross-functional oncology experience of our team with methodologies for generating deep market insights, advanced-analytics platforms, and input from a network of leading external experts. We work to advance cutting-edge oncology innovations (both therapeutic and diagnostic) with pharmaceutical and biotech companies and investors. Approaches we design make it possible for health-care providers to deliver better care, and solutions we propose help health systems and policy makers realize the best possible outcomes for cancer patients. Operating in all geographies, the McKinsey Cancer Center conducts more than 100 client engagements annually across strategy, R&D, business development, marketing and sales, market access and policy, and care-delivery topics. We share our cutting-edge knowledge at international oncology conferences, as well as in peer-reviewed publications and other leading industry journals.
National Cancer Centre (NCC) was established in 2000. It strives to improve national health and welfare by reducing the incidence and mortality of cancer through research, patient care, education & training, and support for the national cancer control programs. "Vision 2020" is a program that represents the organizations goals into the future, where it fights to protect the Korean people from cancer through innovative research, quality medical care, optimal training of cancer experts, and support for national cancer control programs.
Sure, Inc. is a physician-led company focused on one thing: providing a comfortable, accurate breast exam to the 21 million women in the US and the 95% of women globally who are not protected through traditional breast cancer screening.
At Susan G. Komen, we’re committed to doing everything we can to save lives and end breast cancer forever. We strive to support those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. We advocate for strong public policy, fund lifesaving research, empower patients with trustworthy information, improve access to high-quality care and offer treatment assistance and patient support. We are the only breast cancer non-profit with a comprehensive, 360-degree approach to fighting breast cancer across all fronts so that patients can live better lives, longer. In June of 2005, Susan G. Komen became a full UICC member.
The Swiss Cancer League is a national, charitable, private organisation, founded in 1910. It is the Berne-based headquarter of an association of 19 regional cancer leagues. The Swiss Cancer League covers all aspects of cancer, with the aim of ensuring that fewer people develop cancer, fewer people suffer and die from the consequences of cancer and more people can be treated successfully. The organisation supports innovative cancer research projects, increases public awareness of prevention measures and is committed to early diagnosis and treatment. One of its first concerns is to ensure high-quality advice and psychological support for all cancer patients and survivors and their caretakers. The Swiss Cancer League also supports other cancer control organisations in low income countries.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion.
Economist Events brings the rigour of informed analysis and intelligent debate that The Economist is known for to life on stage in international forums. We host over 80 events annually in over 30 countries on topics that convene world-class thought leaders on a range of strategic business issues.
The UNICANCER Group brings together the French Comprehensive Cancer Centers (FCCC), promotes their cancer research organisation and pools resources and competencies to give a new dynamic to patient care. Since their creation in 1945, the French Comprehensive Cancer Centers have held a special place in the French health care system. These private, non-profit establishments are entirely devoted to fighting cancer with a view to public service. They have a threefold mission: patient care, research and teaching. UNICANCER builds on the historical community of the FCCC and accentuates what has always been their strength: cooperating and creating synergies between different teams within the network.
Varian Medical Systems’ mission is to focus energy on saving lives. To meet this challenge, they equip the world with new tools for fighting cancer. Since the 1950s they have been producing tools that harness the power of X-ray energy to benefit humankind. Varian’s history is one of pioneering developments in the fields of radiotherapy, radiosurgery, X-ray tube technology, digital image detectors, cargo screening, and non-destructive testing. Today, they have a robust product portfolio and long-standing relationships with many of the world’s leading clinicians. As Varian continues to grow, their staff of over 6,500 people in 70 sales and support offices around the globe is developing innovative, cost-effective solutions that help make the world a healthier place.
Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Their core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
World Cancer Research Fund International (WCRF International) leads and unifies a global network of cancer charities dedicated to the prevention and control of cancer by means of healthy food and nutrition, physical activity and weight management. In particular, WCRF International plays a leading role in directing and supporting the research activities of the WCRF global network. Working with researchers, health professionals, policy makers and other health organisations throughout the world, we provide people with the information they need to make choices that can reduce their chances of developing cancer. WCRF's vision is that the their global network helps people make choices that reduce their chances of developing cancer. They were the first cancer charity to create awareness of the relationship between diet and cancer risk, to focus funding on research into diet and cancer prevention and to consolidate and interpret global research to create a practical message on cancer prevention.
Boehringer Ingelheim, Cancer Society of Finland, Chinese Medical Association, French League against cancer (La Ligue), Love Hope Strength Foundation, Israel Cancer Association, Jhpiego, Prevent Cancer Foundation.
For more information, please contact:
Lorenzo Boffi, Senior Manager, Partnership Development: firstname.lastname@example.org